Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has recently published a study that showcases the potential of its TURBO-ZM platform to target the human ribosome for therapeutic purposes. The study, titled "A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer," was featured in the prestigious journal Cancer Research Communications. The findings from this research indicate that MYC overexpressing cancers can be effectively targeted by leveraging the heterogeneity of ribosomes in cancer cells. Additionally, preclinical data revealed promising results regarding Eloxx's novel RMA, ZKN-157, and its effectiveness against various subtypes of colorectal cancer.
This groundbreaking research opens up new possibilities for selectively targeting MYC-driven cancers through a unique mechanism and potentially synergizing with existing cancer therapies. Eloxx employs a synthetic chemistry approach to develop innovative RMAs that capitalize on the heterogeneity of ribosomes in cancer cells.